- Investing Ideas
- U.S. Pharmaceuticals & Biotech Top Growth Stocks
U.S. Pharmaceuticals & Biotech Top Growth Stocks
Results
39
39 companies
Axsome Therapeutics
Market Cap: US$10.9b
A biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States.
AXSM
US$207.77
7D
-2.8%
1Y
75.3%
Madrigal Pharmaceuticals
Market Cap: US$12.0b
A biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States.
MDGL
US$516.74
7D
1.8%
1Y
24.6%
TG Therapeutics
Market Cap: US$7.2b
A commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally.
TGTX
US$54.27
7D
11.3%
1Y
84.3%
Insmed
Market Cap: US$27.3b
Develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally.
INSM
US$125.77
7D
1.6%
1Y
-4.6%
AnaptysBio
Market Cap: US$1.7b
A clinical-stage biotechnology company, focuses in delivering immunology therapeutics for autoimmune and inflammatory diseases in the United States.
ANAB
US$57.74
7D
-1.2%
1Y
185.6%
Ardelyx
Market Cap: US$971.8m
Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally.
ARDX
US$3.89
7D
-4.2%
1Y
-36.3%
Ionis Pharmaceuticals
Market Cap: US$9.9b
A commercial-stage biotechnology company, provides RNA-targeted medicines in the United States.
IONS
US$59.74
7D
4.4%
1Y
39.9%
Capricor Therapeutics
Market Cap: US$397.4m
A clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States.
CAPR
US$6.29
7D
-5.4%
1Y
-11.4%
Amylyx Pharmaceuticals
Market Cap: US$4.4b
A clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States.
AMLX
US$38.66
7D
78.7%
1Y
315.7%
Abeona Therapeutics
Market Cap: US$340.8m
A commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States.
ABEO
US$6.09
7D
1.8%
1Y
-15.8%
Cellectar Biosciences
Market Cap: US$24.5m
A clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer in the United States.
CLRB
US$2.59
7D
-0.4%
1Y
-46.9%
Aldeyra Therapeutics
Market Cap: US$90.5m
A biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases.
ALDX
US$1.52
7D
-2.6%
1Y
-73.8%
Zevra Therapeutics
Market Cap: US$706.1m
A commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States.
ZVRA
US$11.87
7D
4.9%
1Y
25.7%
Corcept Therapeutics
Market Cap: US$13.1b
A biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States.
CORT
US$122.25
7D
6.8%
1Y
73.8%
Arcutis Biotherapeutics
Market Cap: US$3.2b
A biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases.
ARQT
US$25.08
7D
-4.2%
1Y
56.9%
Kiniksa Pharmaceuticals International
Market Cap: US$6.1b
A biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally.
KNSA
US$79.03
7D
3.0%
1Y
134.2%
CG Oncology
Market Cap: US$6.9b
A late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States.
CGON
US$79.81
7D
6.4%
1Y
196.5%
Grace Therapeutics
Market Cap: US$45.0m
Engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada.
GRCE
US$2.20
7D
1.9%
1Y
-32.3%
NewAmsterdam Pharma
Market Cap: US$3.3b
A late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease.
NAMS
US$27.87
7D
3.3%
1Y
11.5%
Belite Bio
Market Cap: US$6.5b
A clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics with unmet medical needs in the United States.
BLTE
US$161.06
7D
-1.1%
1Y
150.1%
Sol-Gel Technologies
Market Cap: US$254.1m
Together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel, China, Switzerland, Canada, the United States and internationally.
SLGL
US$77.73
7D
-8.2%
1Y
242.9%
SIGA Technologies
Market Cap: US$213.4m
A commercial-stage pharmaceutical company, focuses on the health security market in the United States.
SIGA
US$3.04
7D
1.3%
1Y
-66.7%
Rhythm Pharmaceuticals
Market Cap: US$7.5b
A commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases in the United States and internationally.
RYTM
US$110.00
7D
-4.7%
1Y
6.5%
Unicycive Therapeutics
Market Cap: US$151.8m
A clinical-stage biotechnology company, identifies, develops, and commercializes therapies for the treatment of kidney diseases in the United States.
UNCY
US$5.63
7D
2.2%
1Y
34.0%
TriSalus Life Sciences
Market Cap: US$322.0m
Engages in the research, development, and commercialization of drug delivery technology platform and immuno-oncology therapeutics to improve outcomes for patients with difficult-to-treat liver and pancreatic cancers in the United States.
TLSI
US$5.27
7D
0%
1Y
4.4%
Aytu BioPharma
Market Cap: US$24.5m
A pharmaceutical company, focuses on commercializing novel therapeutics in the United States and internationally.
AYTU
US$2.37
7D
-0.4%
1Y
7.7%
uniQure
Market Cap: US$3.4b
Develops treatments for patients suffering from rare and other devastating diseases in the United States.
QURE
US$48.37
7D
-0.5%
1Y
208.1%
Liquidia
Market Cap: US$6.4b
A biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States.
LQDA
US$68.62
7D
-7.8%
1Y
155.7%
Iovance Biotherapeutics
Market Cap: US$4.1b
A commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States and internationally.
IOVA
US$8.29
7D
18.8%
1Y
208.2%
Mineralys Therapeutics
Market Cap: US$2.3b
A biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States.
MLYS
US$25.65
7D
0.04%
1Y
72.3%
Fennec Pharmaceuticals
Market Cap: US$398.0m
Operates as a commercial stage biopharmaceutical company in the United States.
FENC
US$11.29
7D
-3.7%
1Y
30.4%
Journey Medical
Market Cap: US$211.4m
A commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States.
DERM
US$7.75
7D
15.3%
1Y
3.7%
Compass Therapeutics
Market Cap: US$425.0m
A clinical-stage oncology-focused biopharmaceutical company, develops antibody-based therapeutics for the treatment of various human diseases in the United States.
CMPX
US$2.40
7D
6.7%
1Y
-20.5%
Gyre Therapeutics
Market Cap: US$732.7m
A pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis.
GYRE
US$6.91
7D
3.4%
1Y
-15.5%
Definium Therapeutics
Market Cap: US$6.1b
A clinical biopharmaceutical company, develops novel product candidates to treat brain health disorders.
DFTX
US$44.91
7D
5.3%
1Y
340.7%
Prothena
Market Cap: US$463.6m
A late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation.
PRTA
US$9.45
7D
6.7%
1Y
7.8%